Search clinical trials for: Ladarixin

Total 14 results

Dompé Farmaceutici S.p.A

Completed

A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers

no Condition

Switzerland
Dompé Farmaceutici S.p.A

Terminated

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

New-onset Type 1 Diabetes

United States, Belgium, Georgia, Germany, Italy, Serbia
Dompé Farmaceutici S.p.A

Completed

A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

Diabetes Mellitus, Insulin-Dependent

Germany, Belgium, Italy
Dompé Farmaceutici S.p.A

Terminated

Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. (CONSERVA)

Type 1 Diabetes

Italy
Dompé Farmaceutici S.p.A

Withdrawn

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Type I Diabetes

United States
Merck Sharp & Dohme LLC

Terminated

Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)

Chronic Obstructive Pulmonary Disease
Dompé Farmaceutici S.p.A

Active, not recruiting

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

New-onset type1 Diabetes

United States, Belgium, Georgia, Germany, Italy, Serbia, Israel, Slovenia
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

Psoriasis
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

Asthma
Merck Sharp & Dohme LLC

Terminated

Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)

COPD
NYU Langone Health

Withdrawn

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

United States
NYU Langone Health

Recruiting

Ladarixin With Sotorasib in Advanced NSCLC

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

United States
Merck Sharp & Dohme LLC

Completed

Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)

Neutrophilic Asthma
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Non-small Cell Lung Cancer | Solid Tumors | Castration Resistant Prostate Cancer | Microsatellite Stable Colorectal Cancer

Canada, United States, Australia, Israel, Korea, Republic of

3

Subscribe